Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 483

1.

Evocalcet, a new oral calcimimetic for dialysis patients with secondary hyperparathyroidism.

Ikejiri K, Akizawa T, Kondo Y, Endo Y, Fukagawa M.

Ther Apher Dial. 2019 Sep 5. doi: 10.1111/1744-9987.13434. [Epub ahead of print] Review.

PMID:
31486206
2.
3.
4.

Considerable international variation exists in blood pressure control and antihypertensive prescription patterns in chronic kidney disease.

Alencar de Pinho N, Levin A, Fukagawa M, Hoy WE, Pecoits-Filho R, Reichel H, Robinson B, Kitiyakara C, Wang J, Eckardt KU, Jha V, Oh KH, Sola L, Eder S, de Borst M, Taal M, Feldman HI, Stengel B; International Network of Chronic Kidney Disease cohort studies (iNET-CKD).

Kidney Int. 2019 Jul 25. pii: S0085-2538(19)30512-5. doi: 10.1016/j.kint.2019.04.032. [Epub ahead of print]

PMID:
31358344
5.

Podocyte Injury Augments Intrarenal Angiotensin II Generation and Sodium Retention in a Megalin-Dependent Manner.

Koizumi M, Ueda K, Niimura F, Nishiyama A, Yanagita M, Saito A, Pastan I, Fujita T, Fukagawa M, Matsusaka T.

Hypertension. 2019 Sep;74(3):509-517. doi: 10.1161/HYPERTENSIONAHA.118.12352. Epub 2019 Jul 29.

PMID:
31352823
6.

Correction to: Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients.

Tsuruya K, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group.

Clin Exp Nephrol. 2019 Sep;23(9):1173. doi: 10.1007/s10157-019-01758-x.

PMID:
31278658
7.

Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study.

Yokoyama K, Fukagawa M, Akiba T, Nakayama M, Ito K, Hanaki K, Wolf M, Hirakata H.

Sci Rep. 2019 Jun 20;9(1):8877. doi: 10.1038/s41598-019-45335-4.

8.

A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.

Fishbane S, Ford M, Fukagawa M, McCafferty K, Rastogi A, Spinowitz B, Staroselskiy K, Vishnevskiy K, Lisovskaja V, Al-Shurbaji A, Guzman N, Bhandari S.

J Am Soc Nephrol. 2019 Sep;30(9):1723-1733. doi: 10.1681/ASN.2019050450. Epub 2019 Jun 14.

PMID:
31201218
9.

Effectiveness of cinacalcet treatment for secondary hyperparathyroidism on hospitalization: Results from the MBD-5D study.

Asada S, Yoshida K, Fukuma S, Nomura T, Wada M, Onishi Y, Kurita N, Fukagawa M, Fukuhara S, Akizawa T.

PLoS One. 2019 May 29;14(5):e0216399. doi: 10.1371/journal.pone.0216399. eCollection 2019.

10.

Semiquantitative analysis of virtual histology derived from intravascular ultrasound images at vascular access stenosis.

Sato T, Otsuka Y, Kikkawa Y, Iwasaki Y, Fukagawa M.

J Vasc Access. 2019 May;20(1_suppl):55-59. doi: 10.1177/1129729818769030.

PMID:
31032725
11.

Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis.

Yokoyama K, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group.

Sci Rep. 2019 Apr 23;9(1):6410. doi: 10.1038/s41598-019-42017-z.

12.

Comprehensive three-dimensional analysis (CUBIC-kidney) visualizes abnormal renal sympathetic nerves after ischemia/reperfusion injury.

Hasegawa S, Susaki EA, Tanaka T, Komaba H, Wada T, Fukagawa M, Ueda HR, Nangaku M.

Kidney Int. 2019 Jul;96(1):129-138. doi: 10.1016/j.kint.2019.02.011. Epub 2019 Apr 9.

PMID:
30979565
13.

Evaluation of changes in ferritin levels during sucroferric oxyhydroxide treatment.

Koiwa F, Yokoyama K, Fukagawa M, Akizawa T.

Clin Kidney J. 2018 Sep 19;12(2):294-299. doi: 10.1093/ckj/sfy077. eCollection 2019 Apr.

14.

Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients.

Tsuruya K, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group.

Clin Exp Nephrol. 2019 Jun;23(6):739-748. doi: 10.1007/s10157-019-01692-y. Epub 2019 Apr 6. Erratum in: Clin Exp Nephrol. 2019 Jul 5;:.

15.

Glucocorticoid Receptor Antagonist Administration Prevents Adrenal Gland Atrophy in an ACTH-Independent Cushing's Syndrome Rat Model.

Yasuda A, Seki T, Kametani Y, Koizumi M, Kitajima N, Oki M, Seki M, Kakuta T, Fukagawa M.

Int J Endocrinol. 2019 Feb 19;2019:8708401. doi: 10.1155/2019/8708401. eCollection 2019.

16.

A Liquid-Based Cytology System, without the Use of Cytocentrifugation, for Detection of Podocytes in Urine Samples of Patients with Diabetic Nephropathy.

Kimura M, Toyoda M, Saito N, Kaneyama N, Miyatake H, Tanaka E, Komaba H, Hara M, Fukagawa M.

J Diabetes Res. 2019 Feb 17;2019:9475637. doi: 10.1155/2019/9475637. eCollection 2019.

17.

The Pituitary Is a Candidate Organ That Modulates Circulating Klotho Levels.

Sato T, Komaba H, Nagatani T, Watanabe T, Kishida Y, Fukagawa M.

J Endocr Soc. 2018 Nov 14;3(1):52-61. doi: 10.1210/js.2018-00223. eCollection 2019 Jan 1.

18.

Response to Comments on "Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study".

Akizawa T, Shimazaki R, Shiramoto M, Fukagawa M; Evocalcet Study Group.

Clin Drug Investig. 2019 Jan;39(1):109-111. doi: 10.1007/s40261-018-0737-y. No abstract available.

19.

Decline in the Functional Status and Mortality in Patients on Hemodialysis: Results from the Japan Dialysis Outcome and Practice Patterns Study.

Matsuzawa R, Kamitani T, Roshanravan B, Fukuma S, Joki N, Fukagawa M.

J Ren Nutr. 2018 Dec 24. pii: S1051-2276(18)30252-8. doi: 10.1053/j.jrn.2018.10.012. [Epub ahead of print]

PMID:
30591357
20.

Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial.

J-DAVID Investigators, Shoji T, Inaba M, Fukagawa M, Ando R, Emoto M, Fujii H, Fujimori A, Fukui M, Hase H, Hashimoto T, Hirakata H, Honda H, Hosoya T, Ikari Y, Inaguma D, Inoue T, Isaka Y, Iseki K, Ishimura E, Itami N, Ito C, Kakuta T, Kawai T, Kawanishi H, Kobayashi S, Kumagai J, Maekawa K, Masakane I, Minakuchi J, Mitsuiki K, Mizuguchi T, Morimoto S, Murohara T, Nakatani T, Negi S, Nishi S, Nishikawa M, Ogawa T, Ohta K, Ohtake T, Okamura M, Okuno S, Shigematsu T, Sugimoto T, Suzuki M, Tahara H, Takemoto Y, Tanaka K, Tominaga Y, Tsubakihara Y, Tsujimoto Y, Tsuruya K, Ueda S, Watanabe Y, Yamagata K, Yamakawa T, Yano S, Yokoyama K, Yorioka N, Yoshiyama M, Nishizawa Y.

JAMA. 2018 Dec 11;320(22):2325-2334. doi: 10.1001/jama.2018.17749.

21.

Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study.

Shigematsu T, Fukagawa M, Yokoyama K, Akiba T, Fujii A, Odani M, Akizawa T.

Clin Ther. 2018 Dec;40(12):2099-2111. doi: 10.1016/j.clinthera.2018.10.016. Epub 2018 Nov 23.

22.

Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study.

Akizawa T, Shimazaki R, Fukagawa M; Evocalcet Study Group.

PLoS One. 2018 Oct 31;13(10):e0204896. doi: 10.1371/journal.pone.0204896. eCollection 2018.

23.

A Retrospective Study on Erythropoiesis Stimulating Agent Dose Reducing Potential of an Anti-Platelet Activation Membrane Dialyzer in Hemodialysis Patients.

Kakuta T, Ishida M, Komaba H, Suzuki H, Fukagawa M.

Ther Apher Dial. 2019 Apr;23(2):133-144. doi: 10.1111/1744-9987.12759. Epub 2018 Oct 11.

PMID:
30311350
24.

Mineral and bone disorder management in hemodialysis patients: comparing PTH control practices in Japan with Europe and North America: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Yamamoto S, Karaboyas A, Komaba H, Taniguchi M, Nomura T, Bieber BA, De Sequera P, Christensson A, Pisoni RL, Robinson BM, Fukagawa M.

BMC Nephrol. 2018 Oct 5;19(1):253. doi: 10.1186/s12882-018-1056-5.

25.

Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan.

Shigematsu T, Shimazaki R, Fukagawa M, Akizawa T.

Clin Pharmacol. 2018 Sep 11;10:101-111. doi: 10.2147/CPAA.S171044. eCollection 2018.

26.

Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans.

Narushima K, Maeda H, Shiramoto M, Endo Y, Ohtsuka S, Nakamura H, Nagata Y, Uchimura T, Kannami A, Shimazaki R, Fukagawa M, Akizawa T.

Clin Transl Sci. 2019 Jan;12(1):20-27. doi: 10.1111/cts.12588. Epub 2018 Oct 24.

27.

Detection of Autonomic Nervous System Abnormalities in Diabetic Patients by 24-hour Ambulatory Blood Pressure Monitoring.

Kimura M, Toyoda M, Ono M, Saito N, Kaneyama N, Miyauchi M, Umezono T, Fukagawa M.

Tokai J Exp Clin Med. 2018 Sep 20;43(3):97-102.

28.

Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study.

Akizawa T, Shimazaki R, Shiramoto M, Fukagawa M; Evocalcet Study Group.

Clin Drug Investig. 2018 Oct;38(10):945-954. doi: 10.1007/s40261-018-0687-4.

29.

Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients.

Shigematsu T, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group.

Clin Exp Nephrol. 2019 Feb;23(2):258-267. doi: 10.1007/s10157-018-1635-6. Epub 2018 Aug 29.

30.

TGF-Beta Signaling in Bone with Chronic Kidney Disease.

Iwasaki Y, Yamato H, Fukagawa M.

Int J Mol Sci. 2018 Aug 10;19(8). pii: E2352. doi: 10.3390/ijms19082352. Review.

31.

Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism.

Fukagawa M, Shimazaki R, Akizawa T; Evocalcet study group.

Kidney Int. 2018 Oct;94(4):818-825. doi: 10.1016/j.kint.2018.05.013. Epub 2018 Jul 24.

32.

New Roles of Parathyroid Hormone.

Fukagawa M.

Ther Apher Dial. 2018 Jun;22(3):216-217. doi: 10.1111/1744-9987.12687. No abstract available.

PMID:
29883063
33.

Critical Governance Issue of Parathyroid Hormone Assays and its Selection in the Management of Chronic Kidney Disease Mineral and Bone Disorders.

Kakuta T, Ishida M, Fukagawa M.

Ther Apher Dial. 2018 Jun;22(3):220-228. doi: 10.1111/1744-9987.12690. Epub 2018 May 20. Review.

PMID:
29781225
34.

Role of Uremic Toxins for Kidney, Cardiovascular, and Bone Dysfunction.

Fujii H, Goto S, Fukagawa M.

Toxins (Basel). 2018 May 16;10(5). pii: E202. doi: 10.3390/toxins10050202. Review.

35.

Emerging Association Between Parathyroid Hormone and Anemia in Hemodialysis Patients.

Tanaka M, Komaba H, Fukagawa M.

Ther Apher Dial. 2018 Jun;22(3):242-245. doi: 10.1111/1744-9987.12685. Epub 2018 May 16. Review.

PMID:
29767854
36.

Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide.

Nakayama M, Tani Y, Zhu WJ, Watanabe K, Yokoyama K, Fukagawa M, Akiba T, Wolf M, Hirakata H.

Kidney Int Rep. 2017 Nov 3;3(2):364-373. doi: 10.1016/j.ekir.2017.10.016. eCollection 2018 Mar.

37.

Secondary Hyperparathyroidism and Protein-Energy Wasting in End-Stage Renal Disease.

Komaba H, Fukagawa M.

Ther Apher Dial. 2018 Jun;22(3):246-250. doi: 10.1111/1744-9987.12683. Epub 2018 Apr 30. Review.

PMID:
29707907
38.

Nutritional status and survival of maintenance hemodialysis patients receiving lanthanum carbonate.

Komaba H, Kakuta T, Wada T, Hida M, Suga T, Fukagawa M.

Nephrol Dial Transplant. 2019 Feb 1;34(2):318-325. doi: 10.1093/ndt/gfy090.

PMID:
29672760
39.

Raltegravir-associated Diabetic Ketoacidosis in a Patient with HIV Infection: A Case Report.

Horikawa M, Toyoda M, Saito N, Kimura M, Kobayashi T, Takagi A, Fukagawa M.

Tokai J Exp Clin Med. 2018 Apr 20;43(1):19-23.

40.

A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.

Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, Hisada Y, Yanagida T, Miyazaki H, Wada M, Akizawa T, Fukagawa M.

PLoS One. 2018 Apr 3;13(4):e0195316. doi: 10.1371/journal.pone.0195316. eCollection 2018.

41.

Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update.

Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND, Vervloet MG, Leonard MB.

Ann Intern Med. 2018 Mar 20;168(6):422-430. doi: 10.7326/M17-2640. Epub 2018 Feb 20.

PMID:
29459980
42.

Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients.

Koiwa F, Yokoyama K, Fukagawa M, Akizawa T.

Kidney Int Rep. 2017 Oct 6;3(1):185-192. doi: 10.1016/j.ekir.2017.10.003. eCollection 2018 Jan.

43.

Interactive Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers or Their Combination on Survival of Hemodialysis Patients.

Kido R, Akizawa T, Fukagawa M, Onishi Y, Yamaguchi T, Fukuhara S.

Am J Nephrol. 2017;46(6):439-447. doi: 10.1159/000482013. Epub 2017 Nov 21.

44.

A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism.

Yokoyama K, Fukagawa M, Shigematsu T, Akiba T, Fujii A, Yamauchi A, Odani M, Akizawa T; ONO-5163 Study Group.

Kidney Int Rep. 2017 Feb 20;2(4):634-644. doi: 10.1016/j.ekir.2017.01.016. eCollection 2017 Jul.

45.

Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate.

Yokoyama K, Fukagawa M, Akiba T, Nakayama M, Otoguro T, Yamada K, Nagamine Y, Fishbane S, Hirakata H.

Kidney Int Rep. 2017 Jan 5;2(3):359-365. doi: 10.1016/j.ekir.2016.12.005. eCollection 2017 May.

46.

[Update on recent progress in vitamin D research. The role of vitamin D in management of CKD-MBD.]

Hamano N, Fukagawa M.

Clin Calcium. 2017;27(11):1609-1614. doi: CliCa171116091614. Japanese.

PMID:
29074834
47.

Magnesium as a new player in CKD: too little is as bad as too much?

Hamano N, Komaba H, Fukagawa M.

Kidney Int. 2017 Nov;92(5):1034-1036. doi: 10.1016/j.kint.2017.05.032.

PMID:
29055421
48.

Adipocytes do not significantly contribute to plasma angiotensinogen.

Koizumi M, Niimura F, Fukagawa M, Matsusaka T.

J Renin Angiotensin Aldosterone Syst. 2016 Oct-Dec;17(4):1470320316672348. doi: 10.1177/1470320316672348.

49.

Erratum to: The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study.

Ogata H, Kumasawa J, Fukuma S, Mizobuchi M, Kinugasa E, Fukagawa M, Fukuhara S, Akizawa T.

Clin Exp Nephrol. 2017 Oct;21(5):809. doi: 10.1007/s10157-017-1459-9. No abstract available.

PMID:
28884458
50.

Secondary Adrenal Insufficiency Following Nivolumab Therapy in a Patient with Metastatic Renal Cell Carcinoma.

Seki T, Yasuda A, Oki M, Kitajima N, Takagi A, Nakajima N, Miyajima A, Fukagawa M.

Tokai J Exp Clin Med. 2017 Sep 20;42(3):115-120.

Supplemental Content

Loading ...
Support Center